Breaking News: Supreme Court Rejects Novartis's Patent Application on Glivec

I have just been informed by well-wishers of the blog that the Supreme Court has dismissed Novartis's Special Leave Petition against the rejection of its patent application on Glivec a.k.a Imatinib Mesylate. The patent application has apparently been rejected on grounds of falling foul of Section 3(d), anticipation and obviousness. Apparently, costs too have been imposed on Novartis for challenging the validity of Section 3(d). 

We will keep our readers posted as and when we get more updates.